Interparfums, Inc. Announces Full Year 2027 Guidance
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Interparfums (IPAR) issued its initial full-year 2027 guidance, projecting higher net sales and diluted earnings per share than it estimates for 2026.
The outlook calls for net sales up 6% to approximately $1.58 billion and diluted earnings per share up 3% to approximately $5.00, versus 2026 estimates of $1.49 billion and $4.85, respectively. Estimated 2026 earnings include a one-time tariff refund gain of $17.9 million, or $0.35 per diluted share. The 2027 outlook assumes no comparable gain. Excluding that benefit from the 2026 comparison, Interparfums expects diluted earnings per share growth of approximately 11%.
The company expects growth from established brands and new fragrances, partly offset by softer performance at smaller brands, expiring licenses and challenges in the Middle East and Eastern Europe. The outlook assumes an approximately 1% currency drag on net sales at current rates.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.2027 net sales guidance projects 6% growth to approximately $1.58 billion from $1.49 billion estimated for 2026
- Minor point. Forward-looking: it has not happened yet and may not happen.2027 diluted EPS guidance projects $5.00 versus $4.85 estimated for 2026, up 3%, or approximately 11% excluding the 2026 tariff refund benefit
- Minor point. Forward-looking: it has not happened yet and may not happen.Established brands and new fragrance launches are expected to drive 2027 sales growth
- Minor point. Forward-looking: it has not happened yet and may not happen.Improved operating efficiency is expected to help lift diluted earnings per share in 2027
- Minor pointNew licensing agreements were signed in 2026
- Minor pointSelect fragrance partnerships were extended in 2026
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.No comparable tariff refund gain is assumed for 2027 after an estimated $17.9 million benefit in 2026
- Minor point. Forward-looking: it has not happened yet and may not happen.Currency movements are expected to reduce 2027 net sales by approximately 1% at current exchange rates
- Minor point. Forward-looking: it has not happened yet and may not happen.Higher brand investment and marketing spending are expected to partly offset 2027 earnings growth
- Minor point. Forward-looking: it has not happened yet and may not happen.Softer performance at smaller brands is expected to partly offset 2027 sales growth
- Minor point. Forward-looking: it has not happened yet and may not happen.Phaseout of some licenses expiring at year-end 2026 and 2027 is expected to partly offset 2027 sales growth
- Minor point. Forward-looking: it has not happened yet and may not happen.Ongoing challenges in the Middle East and Eastern Europe are expected to partly offset 2027 sales growth
Key Figures
- 2027 net sales
- approximately $1.58 billion
- 2027 guidance
- Net sales growth
- +6%
- 2027 guidance
- 2027 diluted EPS
- approximately $5.00
- 2027 guidance
- Diluted EPS growth
- +3%
- 2027 guidance versus 2026 estimate
- EPS growth excluding tariff refunds
- approximately 11%
- 2027 versus 2026, excluding the favorable 2026 tariff-refund impact
- Tariff-refund benefit
- $0.35 per diluted share
- Estimated 2026 benefit; no comparable benefit assumed in 2027 guidance
- Foreign-exchange impact
- approximately 1% unfavorable
- Expected impact on 2027 net sales based upon current rates
Historical Context
-
Raised 2026 sales guidance to $1.49 billion and maintained $4.85 EPS outlook.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced initial guidance for its fiscal year ending December 31, 2027. In evaluating the annual comparison, management noted that full year 2026 estimated results will include the effect of a one-time gain of
| Guidance | 2027E | 2026E | % Change | |
| Net Sales | + | |||
| Diluted EPS | + | |||
*Diluted EPS for 2026 includes an estimated
Management Commentary
Jean Madar, Chairman & Chief Executive Officer of Interparfums stated, “Throughout 2026, we have focused on launching extensions for key fragrance lines across the portfolio, investing in brand marketing, supporting partner and customer demand, and enhancing our operational efficiency. With an eye toward the future, we entered into new licensing agreements, extended select fragrance partnerships, and invested in preparations for blockbuster launches in 2027 − positioning our portfolio to capitalize on evolving consumer demand and supporting long-term growth.”
Mr. Madar continued, “These initiatives have positioned us for a strong 2027. Consolidated net sales are expected to grow
“Diluted EPS is expected to increase
Mr. Madar concluded, “We enter 2027 with momentum and a clear focus on innovation, disciplined investment, and efficient execution to drive profitable growth while navigating a challenging economic backdrop.”
Extensive Line-Up of Blockbusters and Extensions
European Based Operations
For our European based operations, 2027 will benefit from a particularly rich launch plan encompassing initiatives for the portfolio's established brands and contributions from new brands Off-White, Annick Goutal and Longchamp:
- The first half will see the launch of three new franchises for Lacoste, Coach and Montblanc fragrances, which will strengthen the potential of these brands over the coming years;
- The second half will notably benefit from the launch of Longchamp fragrances, the first initiative since the license was signed in July 2025.
In addition to these major initiatives, several line extensions will support the business throughout the year.
United States Based Operations
For our U.S. operations, 2027 will bring an exciting lineup of blockbuster launches and innovative product extensions that will strengthen our established franchises, alongside new product introductions across several other brands. These include:
- New blockbusters, including a new women's fragrance for GUESS in early 2027, a new dual-gender duo for Ferragamo, the launch of Serpentine Man for Roberto Cavalli building on the success of Serpentine, and a new female line for MCM.
- The debut of our first new PUMA fragrances under the exclusive license announced in September 2026, featuring a blockbuster duo for men and women.
In addition to these major launches, we will introduce new extensions and collections across the portfolio, supporting overall growth throughout the year.
About Interparfums, Inc.
Operating in the global fragrance business since 1982, Interparfums, Inc. produces and distributes a wide array of prestige fragrance and fragrance related products under license and other agreements with brand owners. The Company manages its business in two operating segments, European based operations, through its
Our licensed portfolio of prestige brands includes Abercrombie & Fitch, Anna Sui, Boucheron, Coach, Donna Karan/DKNY, Emanuel Ungaro, Ferragamo, Graff, GUESS, Hollister, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Longchamp, MCM, Moncler, Montblanc, Oscar de la Renta, PUMA, Roberto Cavalli, and Van Cleef & Arpels, whose products are distributed in over 120 countries around the world through an extensive and diverse network of distributors. Interparfums, Inc. is also the registered owner of several trademarks including Annick Goutal, Lanvin, Off-White, Rochas, and Solférino.
Forward-Looking Statements
Statements in this release which are not historical in nature are forward-looking statements. Although we believe that our plans, intentions, and expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such plans, intentions, or expectations will be achieved. In some cases, you can identify forward-looking statements by forward-looking words such as “anticipate,” “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “should”, “will”, and “would” or similar words. You should not rely on forward-looking statements, because actual events or results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to, the risks and uncertainties discussed under the headings “Forward Looking Statements” and “Risk Factors” in Interparfums' annual report on Form 10-K for the fiscal year ended December 31, 2025, and the reports Interparfums files from time to time with the Securities and Exchange Commission. Interparfums does not intend to and undertakes no duty to update the information contained in this press release.
Contact Information
Interparfums, Inc.
Michel Atwood
Chief Financial Officer
(212) 983-2640
www.interparfumsinc.com
or
The Equity Group Inc.
Devin Sullivan: (212) 836-9608 /devin.sullivan@theequitygroup.com
Conor Rodriguez: (212) 836-9628 /conor.rodriguez@theequitygroup.com
www.theequitygroup.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.